EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer

Takanori Kurogochi, Akira Matsumoto, Yuya Nyumura, Yuichiro Tanishima, Tomoko Nakayoshi, Tomoyoshi Okamoto, Fumiaki Yano, Ken Eto

Anticancer Research · 2023

DOI: 10.21873/anticanres.16393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Takanori Kurogochi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan; ms03kurogochi@jikei.ac.jp. Hauptthemen laut MEDLINE: Febrile Neutropenia, Docetaxel, Cisplatin, Fluorouracil. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen is an effective form of chemotherapy for advanced esophageal cancer. However, the incidence of adverse events, such as febrile neutropenia (FN), is high. This study retrospectively examined whether pegfilgrastim treatment reduces FN development during DCF therapy. PATIENTS AND METHODS: This study evaluated 52 patients who were diagnosed with esophageal cancer and underwent DCF therapy at Jikei Daisan Hospital, Tokyo, Japan, between 2016 and 2020. They were divided into non-pegfilgrastim and pegfilgrastim-treated groups, and side-effects of chemotherapy and cost-effectiveness of pegfilgrastim were examined. RESULTS: Eighty-six cycles of DCF therapy were conducted (33 and 53 cycles, respectively). FN was observed in 20 (60.6%) and seven (13.2%) cases, respectively (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Febrile NeutropeniaDocetaxelCisplatinFluorouracilAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsFilgrastimPolyethylene GlycolsCost-Effectiveness AnalysisHumansMaleFemaleMiddle AgedAgedAged, 80 and overNeutrophilsLeukocyte Count

Stichwörter der Autor:innen

Esophageal cancercost-effectivenessfebrile neutropeniapegfilgrastim

Substanzen

pegfilgrastimDocetaxelCisplatinFluorouracilFilgrastimPolyethylene Glycols

Autor:innen und Institutionen

  • Department of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan; ms03kurogochi@jikei.ac.jp.
  • Department of Surgery, The Jikei University Daisan Hospital, Tokyo, Japan.
  • Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Zitieren

APA

Kurogochi, T., Matsumoto, A., Nyumura, Y., Tanishima, Y., Nakayoshi, T., Okamoto, T., Yano, F., & Eto, K. (2023). Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16393

Vancouver

Kurogochi T, Matsumoto A, Nyumura Y, Tanishima Y, Nakayoshi T, Okamoto T, et al. Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer. Anticancer Research. 2023. doi:10.21873/anticanres.16393

BibTeX
@article{Kurogochi2023,
  author = {Kurogochi, Takanori and Matsumoto, Akira and Nyumura, Yuya and Tanishima, Yuichiro and Nakayoshi, Tomoko and Okamoto, Tomoyoshi and Yano, Fumiaki and Eto, Ken},
  title = {Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16393}
}
Kostenlos starten →